1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician's choice
    Journal Article

    Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: A phase II, open-label, multicenter, multicohort study
    Journal Article

    Sherman, E.; Lee, J. L.; Debruyne, P. R.; Keam, B.; Shin, S. J.; Gramza, A.; Caro, I.; Amin, R.; Shah, K.; Yan, Y.; more...
    ESMO Open (2023)

    Fulltext@MSK | Save
  • Adjuvant therapy options in renal cell carcinoma — Targeting the metastatic cascade
    Review

    Fitzgerald, K. N.; Motzer, R. J.; Lee, C. H.
    Nature Reviews Urology (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL
    Journal Article

    Hochhaus, A.; Réa, D.; Boquimpani, C.; Minami, Y.; Cortes, J. E.; Hughes, T. P.; Apperley, J. F.; Lomaia, E.; Voloshin, S.; Turkina, A.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
    Journal Article

    Yoshino, T.; Andre, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: A matching-adjusted indirect comparison
    Journal Article

    Rugo, H. S.; Harmer, V.; O’Shaughnessy, J.; Jhaveri, K.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Haftchenary, S.; more...
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the proton collaborative group prospective registry
    Journal Article

    Chhabra, A. M.; Rice, S. R.; Holtzman, A.; Choi, J. I.; Hasan, S.; Press, R. H.; Chang, J.; Halasz, L.; Tsai, H. K.; Wang, C. J.; more...
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
    Journal Article

    Chintala, N. K.; Choe, J. K.; McGee, E.; Bellis, R.; Saini, J. K.; Banerjee, S.; Moreira, A. L.; Zauderer, M. G.; Adusumilli, P. S.; Rusch, V. W.
    Frontiers in Immunology (2023)

    Fulltext@MSK | Save